Detection of Cytokeratin-19 MRNA-positive Cells in the Peripheral Blood and Bone Marrow of Patients with Operable Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Jul 23

PMID 19623181

Citations 44

Authors

A Daskalaki

S Agelaki

M Perraki

S Apostolaki

N Xenidis

E Stathopoulos

E Kontopodis

D Hatzidaki

D Mavroudis

V Georgoulias

Affiliations

Soon will be listed here.

Abstract

Background: To compare detection rates and evaluate the clinical relevance of cytokeratin-19 (CK-19) mRNA-positive cells in the peripheral blood (circulating tumour cells, CTCs) and bone marrow (disseminated tumour cells; DTCs) of patients with early breast cancer.

Methods: Paired samples of peripheral blood and bone marrow were obtained from 165 patients with stage I-II breast cancer before the initiation of adjuvant chemotherapy. In 84 patients, paired blood and bone marrow samples were also available after chemotherapy. The detection of CK-19 mRNA-positive CTCs and DTCs was assessed by real-time PCR.

Results: CK-19 mRNA-positive CTCs and DTCs were detected in 55.2 and 57.6% of patients before chemotherapy, respectively. After chemotherapy, CTCs and DTCs were identified in 44 (52.4%) and 43 (51.2%) of the 84 patients, respectively. There was a 93.9% (McNemar; P=0.344) and 72.6% (McNemar; P=0.999) concordance between blood and bone marrow samples before and after chemotherapy, respectively. The detection of CK-19 mRNA-positive CTCs or DTCs before chemotherapy was associated with decreased overall survival (P=0.024 and P=0.015, respectively). In addition, their simultaneous detection was also associated with an increased incidence of disease-related death and decreased overall survival (P=0.016).

Conclusions: The detection of CK-19 mRNA-positive CTCs using reverse transcription-PCR (RT-PCR) both before and after chemotherapy is correlated with the detection of CK-19 mRNA-positive DTCs in patients with early-stage breast cancer. The determination of the CTC status by RT-PCR conveys clinically relevant information that is not inferior to DTC status and, owing to the ease of sampling, warrants further evaluation as a tool for monitoring minimal residual disease.

Citing Articles

Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer.

Welsch E, Schuster E, Krainer M, Marhold M, Bartsch R, Fischer M Cancers (Basel). 2023; 15(4).

PMID: 36831613 PMC: 9954525. DOI: 10.3390/cancers15041271.

Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients.

Maurer M, Pachmann K, Wendt T, Schott D, Wittig A Curr Oncol. 2021; 28(5):3507-3524.

PMID: 34590615 PMC: 8482075. DOI: 10.3390/curroncol28050302.

Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.

Vilsmaier T, Heidegger H, Schroder L, Trapp E, Zati Zehni A, Rack B Arch Gynecol Obstet. 2020; 303(1):217-230.

PMID: 32929618 PMC: 7854415. DOI: 10.1007/s00404-020-05793-y.

Evaluation of the diagnostic value of circulating tumor cells with CytoSorter CTC capture system in patients with breast cancer.

Jin L, Zhao W, Zhang J, Chen W, Xie T, Wang L Cancer Med. 2020; 9(5):1638-1647.

PMID: 31908156 PMC: 7050089. DOI: 10.1002/cam4.2825.

The Prospect and Challenges to the Flow of Liquid Biopsy in Africa.

Temilola D, Wium M, Coulidiati T, Adeola H, Carbone G, Catapano C Cells. 2019; 8(8).

PMID: 31404988 PMC: 6721679. DOI: 10.3390/cells8080862.

References

Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich C . Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342(8):525-33. DOI: 10.1056/NEJM200002243420801. View

Pantel K, Cote R, Fodstad O . Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91(13):1113-24. DOI: 10.1093/jnci/91.13.1113. View

Benoy I, Elst H, Philips M, Wuyts H, van Dam P, Scharpe S . Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer. 2006; 94(5):672-80. PMC: 2361203. DOI: 10.1038/sj.bjc.6602985. View

Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G . Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993; 85(17):1419-24. DOI: 10.1093/jnci/85.17.1419. View

Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G . Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res. 2004; 10(16):5342-8. DOI: 10.1158/1078-0432.CCR-04-0245. View

Stathopoulos E, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V . Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol. 2005; 16(2):240-6. DOI: 10.1093/annonc/mdi043. View

Pierga J, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N . Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res. 2004; 10(4):1392-400. DOI: 10.1158/1078-0432.ccr-0102-03. View

Ismail M, Wynendaele W, Aerts J, Paridaens R, Gaafar R, Shakankiry N . Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR. Clin Cancer Res. 2004; 10(1 Pt 1):196-201. DOI: 10.1158/1078-0432.ccr-0515-2. View

Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F . Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000; 18(1):80-6. DOI: 10.1200/JCO.2000.18.1.80. View

10.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

11.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A . Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol. 2006; 24(23):3756-62. DOI: 10.1200/JCO.2005.04.5948. View

12.

Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G . Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol. 2007; 18(10):1623-31. DOI: 10.1093/annonc/mdm208. View

13.

Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland J . Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2005; 118(8):2013-9. DOI: 10.1002/ijc.21576. View

14.

Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I . Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007; 25(19):2664-70. DOI: 10.1200/JCO.2006.08.8054. View

15.

Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369(9561):559-70. DOI: 10.1016/S0140-6736(07)60200-1. View

16.

Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland J, Qvist H . Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003; 21(18):3469-78. DOI: 10.1200/JCO.2003.02.009. View

17.

Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A . Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res. 2005; 11(10):3678-85. DOI: 10.1158/1078-0432.CCR-04-2469. View

18.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S . Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009; 27(13):2177-84. DOI: 10.1200/JCO.2008.18.0497. View

19.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

20.

Slade M, Payne R, Riethdorf S, Ward B, Zaidi S, Stebbing J . Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer. 2008; 100(1):160-6. PMC: 2634698. DOI: 10.1038/sj.bjc.6604773. View